Liquid Biopsy Markets, 2023

News provided by

Jul 26, 2019, 19:00 ET

DUBLIN, July 26, 2019 /PRNewswire/ -- The "The World Liquid Biopsy Market" report has been added to ResearchAndMarkets.com's offering.

Liquid biopsies are a set of minimally invasive diagnostic methods that analyze tumor-derived materials that can be found circulating in biological fluids, to provide information for the diagnosis, treatment, and monitoring of cancer.

This report, The World Liquid Biopsy Market contains up-to-date information and useful data points for business planning:

Research vs. Clinical Liquid Biopsy
The Market for Liquid Biopsy by Region
The Market for Liquid Biopsy Market by Type of Analyte
The Market for CTC-based Liquid Biopsy
The Market for ctDNA-based Liquid Biopsy
The Market for EV and Exosome-based Liquid Biopsy
The Market for Multi-Analyte-based Liquid Biopsy
The Market for Other Liquid Biopsy
Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
Selected ctDNA-based Liquid Biopsy Tests in Development
Selected Market-Available CTC-based Liquid Biopsy Tests, 2019
Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2019

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

Early detection and diagnosis / screening
Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
Prognosis of disease

Key Topics Covered:

Chapter One: Executive Summary

Introduction
Liquid Biopsy Technologies
Industry Structure
Liquid Biopsy Market Revenues and Forecast

Chapter Two: Liquid Biopsy Technologies

Introduction
Current Major Liquid Biopsy Technologies

Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy

Introduction
Advantages and Limitations of ctDNA in Liquid Biopsy
Current ctDNA-based Liquid Biopsy Tests
Biocartis
Biocept
Biodesix
CellMax Life
Circulogene
Diacarta
Epigenomics
Foundation Medicine
Guardant Health
Inivata
LungLife AI
Myriad Genetics
NeoGenomics
OncoDNA
Personal Genomic Diagnostics
QIAGEN
Resolution Biosciences
Roche Diagnostics
Sysmex-Inostics
ctDNA-based Liquid Biopsy Tests in Development
Exact Sciences
Freenome
GRAIL
Personal Genome Diagnostics
Tempus

Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy

Introduction
Challenges in the Development of CTC-based Liquid Biopsy Tests
CTC-based Liquid Biopsy Tests
Adaptive Biotechnologies
Biocept
CellMax Life
Epic Sciences
GILUPI
LungLife AI
Menarini-Silicon Biosystems
QIAGEN
CTC-based Liquid Biopsy Tests in Development
ANGLE
Epic Sciences
Liquid Biotech USA

Chapter Five: Extracellular Vesicles and Other Liquid Biopsy

Introduction
Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
Biodexis
Exosome Diagnostics
Hologic
MDxHealth
Vermillion
Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
Circulogene
OncoCyte
QIAGEN
Resolution Biosciences
VolitionRx

Chapter Six: Multi-Analyte Liquid Biopsy Tests

Introduction
Liquid Biopsy Tests Based on Multiple Analytes
Biocept
Biodesix
Foundation Medicine
LungLife AI
NeoGenomics
OncoDNA
Multiple Analyte-based Liquid Biopsy Tests in Development
Exact Sciences
Freenome
GRAIL
LungLife AI

Chapter Seven: Liquid Biopsy Tests for Research Use Only

Introduction
Liquid Biopsy Tests for Research Use Only
Agena Bioscience
ANGLE
DiaCarta
Exosome Diagnostics
Guardant Health
Natera
QIAGEN

Chapter Eight: Liquid Biopsy Industry Analysis

Introduction
Tiers of Competition
Competitive Factors
Significant Market Trends
Personalized Medicine
Increasing Global Life Expectancy
New Liquid Biopsy Products
Increasing Accessibility of Genetic Testing
Regulatory Hurdles
Third-Party Payor Coverage
Demonstrated Clinical Utility
Incidence Rates of Specific Cancers
Competitors No Longer in the Liquid Biopsy Market

Chapter Nine: Liquid Biopsy Market

Market Overview
Market Forecast

Chapter Ten: Market by Analyte

Circulating Tumor DNA
Market Overview
Revenue Forecast
Circulating Tumor Cells
Market Overview
Revenue Forecast
Extracellular Vesicles and Other Analytes
Market Overview
Revenue Forecast
Multiple Analytes
Market Overview
Revenue Forecast
Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2018-2023

Chapter Eleven: Market by Application

Therapy Guidance and Monitoring
Market Overview
Revenue Forecast
Diagnosis/Screening
Market Overview
Revenue Forecast
Disease Prognosis
Market Overview
Revenue Forecast

Chapter Twelve: Market by Cancer Type

Breast Cancer
Market Overview
Revenue Forecast
Colorectal Cancer
Market Overview
Revenue Forecast
Lung Cancer
Ovarian Cancer
Prostate Cancer
Other Cancers
Pan-Cancer Tests

Chapter Thirteen: Liquid Biopsy Company Profiles

Top Ten Companies in the Liquid Biopsy Market
Adaptive Biotechnologies
Agena Bioscience, Inc.
ANGLE, plc
Biocartis Group NV
Biocept, Inc.
Biodesix
CellMax Life
Circulogene
DiaCarta, Inc.
Epic Sciences
Epigenomics AG
Exact Sciences
Exosome Diagnostics, Inc.
Foundation Medicine, Inc.
Freenome, Inc.
Genomic Health, Inc.
GILUPI GmbH
GRAIL
Guardant Health, Inc.
Hologic
Inivata
Liquid Biotech USA
LungLife AI (formerly Cynvenio Biosystems)
MDxHealth
Menarini-Silicon Biosystems, Spa
Myriad Genetics, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
OncoCyte Corporation
OncoDNA S.A.
Personal Genome Diagnostics
QIAGEN N.V.
Cell-free DNA Technologies
CTC Technologies
Exosome and miRNA Technologies
Resolution Biosciences
Roche Diagnostics
Sysmex-Inostics, Inc.
Tempus
Vermillion, Inc.
VolitionRx

For more information about this report visit https://www.researchandmarkets.com/r/1xjxk6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets